Headlands Technologies LLC Sells 809 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Headlands Technologies LLC decreased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 6.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,260 shares of the company’s stock after selling 809 shares during the quarter. Headlands Technologies LLC’s holdings in TransMedics Group were worth $702,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in TransMedics Group by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock valued at $226,700,000 after buying an additional 40,860 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of TransMedics Group by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 772,744 shares of the company’s stock worth $48,191,000 after acquiring an additional 8,954 shares in the last quarter. Emerald Advisers LLC raised its holdings in shares of TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after purchasing an additional 220,804 shares during the last quarter. Norges Bank bought a new stake in shares of TransMedics Group in the fourth quarter worth $22,861,000. Finally, Vaughan Nelson Investment Management L.P. boosted its holdings in TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after purchasing an additional 32,605 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TMDX has been the topic of several recent research reports. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $73.11 on Thursday. The company has a market cap of $2.46 billion, a P/E ratio of 77.78 and a beta of 2.12. The firm’s fifty day moving average price is $69.76 and its two-hundred day moving average price is $86.43. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.